RETATRUTIDE

---

Retatrutide (LY3437943) is a triple-agonist peptide that activates GLP-1, GIP, and Glucagon receptors simultaneously.

It represents the next generation of metabolic research peptides, designed to enhance energy expenditure, improve glucose control, and accelerate fat loss beyond what dual-agonists like Tirzepatide can achieve.

 Retatrutide combines three powerful pathways:

1. GLP-1 Receptor Agonism – reduces appetite, slows gastric emptying, increases insulin secretion.
    
2. GIP Receptor Agonism – enhances insulin response and fat metabolism.
    
3. Glucagon Receptor Agonism – increases basal metabolic rate and promotes lipid oxidation.
    

Together, they produce synergistic metabolic effects, making Retatrutide one of the most potent peptides ever studied for weight management and energy balance.

 Metabolic control:

Improved glucose tolerance & insulin sensitivity

Body composition:

Significant reduction in total & visceral fat mass

Energy expenditure:

Increased metabolic rate through glucagon activation

Cardiometabolic health:

Improved lipid profiles & inflammatory markers

Lean-mass preservation:

Favorable body-recomposition outcomes

Weeks 1–4   2 mg once weekly

Initial titration phase

Weeks 5–8   4 mg once weekly

Improved tolerance & metabolic activation

Weeks 9–12   8 mg once weekly

Typical working range

Weeks 13–16   12 mg once weekly

Enhanced lipid oxidation

Weeks 17 +  16 mg once weekly (max studied)

High-end maintenance